FORMULATION DEVELOPMENT AND EVALUATION OF TYROSINE KINASE INHIBITOR IMATINIB LOADED ORGANOGEL
Keywords:
Imatinib, Organogel, Transdermal Delivery, Reverse Micelles, Controlled Release.Abstract
This study explores the development and evaluation of a transdermal delivery system for Imatinib mesylate using a pluronic lecithin organogel (PLO). Imatinib, a tyrosine kinase inhibitor used in treating chronic myeloid leukemia and gastrointestinal stromal tumors, suffers from poor oral bioavailability and gastrointestinal side effects. To address these issues, reverse micelles were formulated using lecithin in isopropyl myristate, then transformed into a gel using Pluronic F127. The resulting PLO was characterized for physicochemical properties including pH, viscosity, drug content, spread ability, and in vitro drug release. The optimized formulation showed homogeneity, ideal pH (6.6), appropriate gel strength, high drug content (90.83%), and sustained release over 8 hours (46.02%). Morphological studies confirmed Nano-sized, spherical particles with an encapsulation efficiency of 47%. This organogel system shows promise as a stable, effective, and patient-friendly alternative for topical Imatinib delivery in cancer therapy.
References
• Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., ... & Sawyers, C. L. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine, 344(14), 1031-1037.
• Peng, B., Lloyd, P., & Schran, H. (2004). Clinical pharmacokinetics of imatinib. Clinical Pharmacokinetics, 43(12), 723-741.
• Fang, J. Y., Hwang, T. L., Huang, Y. L., & Wu, P. C. (2008). Lipid-based formulations for enhancing the skin delivery of drugs. International Journal of Pharmaceutics, 370(1–2), 70–77.
• Zhang, R., Zhang, L., & Somasundaran, P. (2004). Study of mixtures of n-dodecyl-β-d-maltoside with anionic, cationic, and nonionic surfactant in aqueous solutions using surface tension and fluorescence techniques. Journal of colloid and interface science, 278(2), 453-460.
• Vrignaud, S., Hureaux, J., Wack, S., Benoit, J. P., & Saulnier, P. (2012). Design, optimization and in vitro evaluation of reverse micelle-loaded lipid nanocarriers containing erlotinib hydrochloride. International journal of pharmaceutics, 436(1-2), 194-200.
• Mackeben, S., & Müller-Goymann, C. C. (2000). Solubilization of timolol maleate in reversed micellar systems: measurement of particle size using SAXS and PCS. International journal of pharmaceutics, 196(2), 207-210.
• Lyu, A., & Wang, Q. (2018). Dermatofibrosarcoma protuberans: A clinical analysis. Oncology letters, 16(2), 1855-1862.
• Pawar, S. A., Patil, M. P., Sadgir, P. S., & Wankhede, N. B. (2014). Review on organogel as topical delivery system. World J Pharm Sci, 3(10), 393-409.
• Dorothee Le Garrec, Maxime Ranger and Jean-Christophe Leroux Micelles in Anticancer Drug Delivery (2004) Healthcare Technology Review 2 (1): 15-42.
• Jhawat, V., Gupta, S., & Saini, V. (2016). Formulation and evaluation of novel controlled release of topical pluronic lecithin organogel of mefenamic acid. Drug delivery, 23(9), 3573-3581.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Sunil Dua, Dr. Ragini Bundela, Dr. Karunakar Shukla, Dr. Neha Jain
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of this journal: Copyright © 2023 American Journal of Medical Science and Chemical Research (Journaloms), its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open-access content, the Creative Commons licensing terms apply.
